Cargando…
Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
The most common EGFR mutations in non‐small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to EGFR‐tyrosine kinase inhibitors. However, rare EGFR mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A C...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983145/ https://www.ncbi.nlm.nih.gov/pubmed/29673089 http://dx.doi.org/10.1111/1759-7714.12637 |